نتایج جستجو برای: ESO
تعداد نتایج: 3679 فیلتر نتایج به سال:
A two-stage optimization method is presented by employing the evolutionary structural optimization (ESO) and ant colony optimization (ACO), which is called ESO-ACO method. To implement ESO-ACO, size optimization is performed using ESO, first. Then, the outcomes of ESO are employed to enhance ACO. In optimization process, the weight of double layer grid is minimized under various constraints whi...
سابقه و هدف: ژن‌های سرطانی- بیضه‌ایی (Cancer-Testis genes) فقط در بافت نرمال بیضه بیان می‌شوند، ولی برخی از آنها در بعضی از انواع سرطان‌ها بیان می‌شوند. هدف از این مطالعه بررسی کیفی بیان چند ژن سرطانی- بیضه‌ایی در بافت توموری بیماران مبتلا به سرطان پستان بود.روش بررسی: پس از تهیه 32 نمونه سرطان پستان و استخراج RNA، با روش Multiplex RT-PCR، بیان رونوشت ژن‌های سرطانی- بیضه‌ایی NY-ESO-1 1a،NY-ES...
سابقه و هدف: ژن های سرطانی- بیضه ایی (cancer-testis genes) فقط در بافت نرمال بیضه بیان می شوند، ولی برخی از آنها در بعضی از انواع سرطان ها بیان می شوند. هدف از این مطالعه بررسی کیفی بیان چند ژن سرطانی- بیضه ایی در بافت توموری بیماران مبتلا به سرطان پستان بود.روش بررسی: پس از تهیه 32 نمونه سرطان پستان و استخراج rna، با روش multiplex rt-pcr، بیان رونوشت ژن های سرطانی- بیضه ایی ny-eso-1 1a،ny-eso-...
NY-ESO-1 is a 180 amino-acid human tumor antigen expressed by many different tumor types and belongs to the family of "cancer-testis" antigens. In humans, NY-ESO-1 is one of the most immunogenic tumor antigens and NY-ESO-1 peptides have been shown to induce NY-ESO-1-specific CD8(+) CTLs capable of altering the natural course of NY-ESO-1-expressing tumors in cancer patients. Here we describe the...
PURPOSE NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of expression by immunohistochemistry (IHC) and the degree of inherent immunogenicity to NY-ESO-1. EXP...
The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their characteristics. We found detectable Ab ...
The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of outcome in patients with multiple myeloma (MM). Gene expression profiling (GEP) of such patients showed increased expression of NY-ESO-1 compared to patients with normal cytogenetics (60% versus 31%; P = .004). NY-ESO-1 was also highly expressed in relapsing MM especially patients with CA (100% versus 60.7...
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor types. Patients with advanced NY-ESO-1-expressing tumors frequently develop humoral immunity to NY-ESO-1, and three HLA A2-restricted peptides were defined previously as targets for cytotoxic CD8(+) T cells in a melanoma patient with NY-ESO-1 antibody. The objectives of...
Evidence is growing for both humoral and cellular immune recognition of human tumor antigens. Antibodies with specificity for antigens initially recognized by cytotoxic T lymphocytes (CTLs), e.g., MAGE and tyrosinase, have been detected in melanoma patient sera, and CTLs with specificity for NY-ESO-1, a cancer-testis (CT) antigen initially identified by autologous antibody, have recently been i...
PURPOSE NY-ESO-1 (ESO), a tumor-specific antigen of the cancer/testis group, is presently viewed as an important model antigen for the development of generic anticancer vaccines. The ESO(119-143) region is immunodominant following immunization with a recombinant ESO vaccine. In this study, we generated DRB1*0101/ESO(119-143) tetramers and used them to assess CD4 T-cell responses in vaccinated p...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید